

MGC Pharmaceuticals Ltd

11:50 07 Aug 2020

MGC Pharmaceuticals higher after confirming effectiveness of ArtemiC on human immune cells to inflammatory stimuli

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKTS:MGCLF) has surged 41% this morning after results from pre-clinical in-vitro laboratory tests which have shown effective immunological activity for the use of ArtemiC as an immunomodulatory agent for the treatment of COVID-19.

The in-vitro immunological evaluations were conducted by independent clinical research laboratory, MyPlant Bio, Israel.

A final report of results from the testing supports the claim that ArtemiC can modify the function of human immune cells in response to inflammatory stimuli.

Specifically, some elements of the formulation demonstrated an effective response on immune function in a manner considered desirable in the treatment of COVID-19.

Shares higher

MGC Pharma's shares are trading higher and this morning have been up as much as 41% to 3.1 cents.

The study was a preclinical in-vitro immunological evaluation of the micellized-formulations and were designed to test the effect of ArtemiC and its ingredients (consisting of Artemisinin, Vitamin C, Curcumin, Boswellia serrata) on responses of human Peripheral Blood Mononuclear Cells (PBMCs) to inflammatory stimuli.

"Very pleased" with results

Co-founder and MD Roby Zomer said: "We are very pleased to have achieved these results, which have been completed in line with FDA requirements for COVID-19 studies and provide important data points for our Phase IIb and III trial design and protocols."

The evaluation was conducted in a model serving the study of the Cytokine Storm Syndrome, a model noted by the FDA to be a good predictor for cytokine storm response and immunotoxicity.

When the production of cytokines is excessive and uncontrolled it is described as a 'Cytokine Storm'.

This phenomenon occurs due to failure to contain the body's reaction to stimuli that occur in response to infection.

The severe clinical deterioration due to COVID-19 is attributed to a significant degree to these circumstances of Cytokine Storm and serves a representative example of the fatal consequences that such a failure may entail.

ArtemiC can reduce inflammation risk

Price: 0.022

Market Cap: \$36.1 m

1 Year Share Price Graph



Share Information

Code: MXC

Listing: ASX

52 week High Low
0.042 0.015

Sector: Cannabis

Website: www.mgcpharma.com.au

Company Synopsis:

MGC Pharmaceuticals Ltd (ASX:MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines.

action@proactiveinvestors.com.au

The study results indicate that ArtemiC can reduce the risk of inflammation by diminishing the release of the interleukins (IL-1 β and IL-6) from PBMCs in response to standard stimulation by exposure to Lipopolysaccharide (LPS).

Interleukins trigger inflammation and modulate the immune response, and Lipopolysaccharide (LPS) is an agent that causes the production of cytokines that leads to cytokines storm.

These results are considered particularly important by the Company and its clinical research team as IL-6 has been implicated in the exacerbation of COVID-19 clinical deterioration.

Research data suggests that the combination of the active ingredients of ArtemiC is more potent and does elicit an in-vitro effect on immunological response during a disease.

Further studies underway

Further studies are underway and planned to augment these initial findings to evaluate the preferable ratios between the active ingredients.

MGC is currently awaiting the first interim results from the COVID-19 infected patients from the Phase II randomised, double-blind clinical trial underway in Israel, which are expected to be finalised shortly.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).